Patients ( N = @ ) aged @ to @ years ( mean age , @ years ) with poorly controlled persistent allergic asthma , less than @ % adherence to inhaled corticosteroid therapy , a forced expiratory volume in @ second ( FEV@ ) of @ % predicted or higher , and adenosine provocation concentration that caused a decrease in FEV@ of @ % ( PC@ ) of @ mg/mL or less were randomized to receive @ months of omalizumab or placebo in a double-blind , crossover trial with a @ - to @-month washout between treatments .